Several of the signs and symptoms of pulmonary embolism, such as dyspnea, tachypnea, and tachycardia, are common in the obese population, so these patients are frequently suspected of having a pulmonary embolism. Establishing an accurate diagnosis in this situation is often difficult. We performed a review of the literature examining the difficulty of diagnosing pulmonary embolism in obese patients. Several factors compromise the ability of clinicians to accurately diagnose pulmonary embolism in obese patients. When patients weigh over 350 lbs (159 kg), thoracic imaging often cannot be performed because of the weight limitations of the scanning equipment. If equipment is available that can scan these patients, image quality is often poor. The literature that is available to guide the clinician in this difficult clinical scenario is sparse. Access to radiology equipment that can image morbidly obese patients is improving, but questions about image quality remain. Further research on both imaging and outcomes is needed.
Introduction
Obesity is defined as a body mass index (BMI) of greater than 30, and morbid obesity is defined as a BMI of greater than 40. The number of obese patients in the United States (USA) continues to climb on a yearly basis, with the ageadjusted prevalence in 2008 for obesity and morbid obesity being 34% and 6%, respectively. 1 Obese patients are at increased risk for pulmonary embolism (PE), and clinicians are now frequently asked to diagnose and treat obese patients with signs and symptoms suggestive of PE. Imaging limitations in the obese population are common 2 and establishing a definitive diagnosis in the obese patient with suspected PE can be problematic. An inaccurate diagnosis in this situation can lead to adverse outcomes and malpractice litigation. The difficulty of diagnosing PE in the obese population has not been discussed in several recent reviews of the diagnosis and treatment of PE [3] [4] [5] [6] [7] and was not mentioned in a recent review of obesity and respiratory diseases. 8 This is the first literature review in the English language on the topic of the difficulty of diagnosing PE in the obese patient.
Methodology
A systematic review of the literature available on obesity and PE was performed with special emphasis on the imaging limitations frequently encountered in this situation. MEDLINE, PUBMED CENTRAL, and Embase were searched from January 1990 to December 2010 for case studies, reviews, and research studies. Keywords used for the search included obesity and the modifiers thromboembolic disease, pulmonary embolism, electrocardiography, echocardiography, radiology, lower extremity venous duplex, venography, pulmonary angiography, ventilation/perfusion lung scan and computerized tomographic pulmonary angiography. Additional articles were identified by hand-searching the references included in pertinent articles and by contacting known experts in the field. Those articles felt to be clinically relevant were included in this review. Proprietary information associated with current technology and equipment is not available in scholarly databases, but was sought by searches on the internet and by directly contacting manufacturers.
Obesity as a risk factor for thromboembolic disease
Multiple studies have examined the relationship between obesity and thromboembolic disease. In a case-control study of 454 patients with a first episode of objectively diagnosed thrombosis, Abdollahi et al. found that obesity increased the risk of thrombosis twofold. 9 When obese women in this study used oral contraceptives, the risk of thrombosis was 10-fold higher than normal. Stein et al. performed a retrospective review of the database of the National Hospital Discharge Survey from 1979 to 1999. 10 By comparing the discharge codes for obesity and thromboembolic disease, the authors determined that the relative risk for PE was 2.21 in obese patients. A recent analysis of nearly seven million hip and knee arthroplasty procedures performed in the USA between 1990 and 2004 determined that obesity increased the risk of postoperative PE in these procedures by a factor of 2.7. 11 The only prospective data on the risk of PE in obese patients is from the Nurse's Health Study which began following 112,822 women in 1976. The first analysis of this data, covering 1976-1992, showed that obese women had a relative risk for PE of 2.9. 12 A follow-up publication on this same cohort covering 1984-2002 showed a strong linear positive association between BMI and the risk of idiopathic PE, with the risk for PE increased nearly sixfold among women with a BMI greater than 35. 13 The cause for the increased risk for thromboembolic disease in obese patients is multifactorial, stemming from both mechanical issues and hypercoagulability. A recently published study from Switzerland demonstrated an inverse correlation between both waist-to-hip ratios and waist circumference and lower limb venous flow. 14 Multiple studies have suggested that obesity itself is a hypercoagulable state, 9, [15] [16] [17] identifying obesity-associated increases in coagulation factors, markers of thrombin generation, fibrin production, and fibrin turnover.
Signs and symptoms of PE in obese patients
The signs and symptoms of PE are non-specific. This is proven by the fact that only 20% of all patients with suspected PE are found to have the illness. 18, 19 The clinical diagnosis of PE is especially difficult in the obese patient. Dyspnea is the most frequent symptom of PE, followed by chest pain. 20 Dyspnea at rest is a common complaint in normal obese people. Sahebjami studied 23 healthy obese men and found that 15 of the subjects were dyspneic at rest. The dyspneic subjects had an average BMI of 37, and this symptom was related to BMI, maximum static expiratory mouth pressure, and peripheral airway disease. 21 The physical exam is challenging in the obese patient with suspected PE (Table 1) . A recent editorial has pointed out that the physical exam of the obese patient is "undermined when the viscera and vasculature are enveloped in a thick layer of adipose tissue". 22 Obesity itself is not included as a component of any of the commonly used standardized clinical decision rules to determine the clinical probability of PE including the Geneva score, the Wells prediction rule, or the PERC criteria used in emergency rooms to determine the need for additional testing in patients with suspected PE. [23] [24] [25] Tachycardia and tachypnea are the two most common signs found in PE. Tachycardia is a component of both the Wells prediction rule and the PERC criteria. 24, 25 However, obesity can cause significant tachycardia, and the heart rate increases in a linear fashion with the BMI. 26 A 1984 study showed that respiratory rates in normal resting obese patients (body weight greater than 190% of predicted ideal weight) are typically 40% higher than non-obese patients. 27 A recent PE propensity scoring system from Italy includes wheezing as a negative predictor of PE, 28 but breath sounds are often difficult to hear in the overweight patient. 22 Lastly, leg edema and chronic skin changes are common in obesity, making the detection of deep vein thrombosis (DVT) difficult. Since many obese patients have chronic signs and symptoms which mimic PE, clinicians should pay particular attention to an acute worsening of pre-existing signs or symptoms which may suggest that an acute event such as a PE has occurred.
Laboratory testing
Hypoxemia is often the first clue that a PE has occurred. Hypoxemia at rest is common in obese patients without underlying lung disease, primarily secondary to ventilation/ perfusion mismatch, although hypoventilation plays a role in those patients with the obesity hypoventilation syndrome. 29, 30 In a comprehensive review, Zavorsky and Hoffman compiled data from 41 different studies examining pulmonary gas exchange in morbidly obese individuals. 31 The arterial pressure of oxygen at rest in the total data base of 768 subjects with a mean BMI of 48 was 17 mm below predicted, and paO 2 values as low as 50 mm were seen in this population. They also point out that the expected paO 2 for a morbidly obese patient varies inversely with both waist circumference and waist-to-hip ratio. D-dimer, brain natriuretic protein (BNP), and troponin are commonly used in the evaluation of patients with suspected PE. A normal high-sensitivity quantitive D-dimer is useful in ruling out PE in a patient with a low or moderate clinical probability of PE determined by a validated clinical decision rule. 24, [32] [33] [34] [35] D-dimer values are elevated in obese patients, and there are studies showing a positive correlation between D-dimer values and waist circumference 16 and BMI. 36 BNP and troponin levels are used as markers for right ventricular stress and are employed in some protocols as part of a risk stratification program to determine whether thrombolytic therapy should be considered. 3, 37 BNP values are higher in PE patients than patients with other pulmonary diseases who present with dyspnea. 38 The relationship between BNP values and obesity is complex. BNP values are generally lower in obese patients than nonobese patients. 39 However, as BMI increases, the presence of diastolic dysfunction increases, and there is a direct correlation between diastolic dysfunction and BNP values. 40 The effect of obesity on troponin levels has not been studied.
Electrocardiography (EKG) and echocardiography
Morbid obesity causes several changes in the EKG, including low voltage, flattening of the T waves, and axis changes, thereby rendering EKG interpretation more difficult in this population. 26, 41 Most experts now feel that the role of the EKG in diagnosing PE is quite limited. 42 In particular, the clinical usefulness of specific EKG patterns (i.e. S1Q3T3) in diagnosing PE has been called into question. A 2004 study of EKG findings in 49 emergency room patients with PE did not identify any EKG features that distinguished patients with PE from those without PE. 43 In fact, only one of the patients with PE had a S1Q3T3 pattern on their EKG. Perhaps the most useful role of the EKG in the evaluation of the obese patient with suspected PE is the detection of alternative diagnoses such as acute coronary syndromes or pericarditis.
Echocardiography is being used more frequently in patients with suspected and proven PE. The majority of PE patients have a normal echocardiogram, and the PE patients who do exhibit right ventricular dysfunction or strain appear to have a higher mortality rate than the PE patients with normal right ventricular function. 44 Clinically unexplained pulmonary hypertension or right ventricular dysfunction may be clues which lead to a diagnosis of PE. 45 However, high pulmonary artery pressures are common in patients with a BMI over 30. A 2001 study examined the clinical correlates affecting pulmonary artery pressures in 3790 patients with normal echocardiograms. 46 The study found a direct correlation between BMI and right ventricular systolic pressure (RVSP), and the authors concluded that a RVSP value up to 40 mmHg should be considered normal in obese patients.
Lower extremity venous duplex (LEVD)
Sixty percent of patients with documented PE have DVT of the lower extremities detected with LEVD. 47 Since the test is non-invasive, it is often used as part of the diagnostic workup in patients with suspected PE, especially in obese patients who cannot undergo diagnostic thoracic imaging because of their size. Unfortunately, ultrasound images are affected by the increased tissue depth of obesity to a greater degree than any other imaging modality. 48 Garg et al. found that obesity limited visualization of the distal superficial veins in 20 of 70 consecutive patients with suspected PE. 49 This study compared the imaging accuracy of LEVD with computerized tomographic (CT) venography, and CT venography provided better images than LEVD in eight of the 15 patients in the greater-than-100 kg weight group. The large deep veins of the thigh are usually adequately visualized with LEVD in obese patients, and since most experts agree that most clinically significant PE embolize from these veins, 4 the data derived from LEVD studies is often clinically useful. In those patients with possible thromboembolic disease who initially have a negative LEVD study, serial follow-up studies can be useful in monitoring the patient for the development of DVT. 50
Lower extremity venography and pulmonary angiography
Lower extremity venography and pulmonary angiography have largely been replaced by less invasive studies. Both lower extremity venography and pulmonary angiography are usually performed in the angiography suite on a fluoroscopy table. Imaging of the obese in this setting is limited by the actual weight the table can hold, the ability of the motors to move the table, and the space between the tabletop and the imaging tower. 51 These tables usually have weight limits in the range of 350-500 lbs (159-227 kg). 52 Cardiac catheterization has been successfully performed in patients who exceed the angiography table weight limit by supporting much of the patient's weight on a stretcher placed perpendicular to the angiography table. 53 This method has never been reported for lower extremity venography or pulmonary angiography.
Lower extremity venography often cannot be performed on obese patients because accessing an adequate lower extremity vein is impossible secondary to the obesity, edema, and chronic skin changes. No research has been conducted about image quality for obese patients who can successfully have lower extremity venography, but the fact that obesity interferes with image quality in other angiography studies such as coronary angiography 54 likely means that similar problems occur with both lower extremity venography and pulmonary angiography.
Few pulmonary angiograms are being done because of the proven efficacy of the less invasive computerized tomographic pulmonary angiography (CTPA). No studies have addressed the issue of image quality in obese patients undergoing pulmonary angiography, and the percentage of pulmonary angiograms in obese patients which are uninterpretable is unknown. Since pulmonary angiograms are infrequently performed, this question will probably remain unanswered.
Ventilation/perfusion (V/Q) lung scanning
The sensitivity and specificity of V/Q scanning have always been low in all patients, and a truly 'diagnostic' result (normal/near normal or a high probability result) is only obtained in 27% of V/Q scans. 55 Most V/Q scans are done in the horizontal position using a biplanar nuclear imaging device which obtains two views at the same time. The ventilation scan is performed first, followed by the perfusion scan.
The table weight limits for nuclear imaging tables are usually in the range of 300-450 lbs (136-204 kg). 48 If the patient exceeds this weight limit, then some institutions will attempt doing an 'upright' or 'vertical' V/Q scan using either the biplane equipment in a vertical mode or a single head camera. The patient is usually required to sit motionless for a prolonged period of time (often greater than an hour) on a stool while the study is completed. Some institutions feel that this is an unsafe situation in a patient with suspected PE, and they do not allow this type of scan to be performed. If a single head scanner is used, only three or four images can be performed as opposed to the usual eight with a standard V/Q scan. In addition, the field of vision for this type of scanner is usually limited, and this leads to 'cropping' of the images on these large patients. These limitations often cause the test to be either suboptimal or uninterpretable. There are no studies examining the efficacy of the upright V/Q scan in the obese patient with suspected PE.
Some patients with severe truncal obesity who do not exceed the weight limit of the nuclear medicine table cannot be scanned because their large girth makes it impossible for them to fit between the two heads of the biplanar scanner. The distance between the heads is commonly 60 cm, and this is not adjustable on most scanners. In this scenario, a single plane scanner can be used, but this significantly lengthens the time required to do the test and may adversely affect the quality of the images, as described above.
There are no published studies examining the relationship between image quality and weight in V/Q scanning, but image quality is commonly severely compromised in the obese patient undergoing V/Q scanning 51 (Table 2 ). In the USA, the dose of radioisotopes is based on weight and there is a maximal allowable dose. Some morbidly obese patients exceed this maximal dose and therefore receive an inappropriately low dose for their weight, resulting in inadequate images. There is a case report from The Netherlands in which a very high dose of radioisotope was successfully used to scan a 554 lb (251 kg) patient with a PE, 56 but this practice is presently not approved in the USA.
Computerized tomographic pulmonary angiography
CTPA has largely replaced V/Q scanning as the preferred diagnostic modality for PE because of its increased sensitivity and specificity and its ability to identify alternative diagnoses. At Grant Medical Center, a 640 bed level I trauma center in Columbus, Ohio, 2313 CTPA studies were performed during 2007, as opposed to only 100 V/Q scans.
Similar to V/Q scanning, obesity can interfere with the performance of CTPA via three mechanisms: weight limits, inability to physically fit into the scanner, and poor image quality. The weight limits of CT scanners are actually determined by the motors which move the table in a very precise manner. Attempting to do a scan on a patient who exceeds the prescribed weight limit for a particular CT scanner may lead to poor image quality and damage to the motors.
In 2008, Ginde et al. published a study in which they surveyed 136 US academic hospitals and a random sampling of all non-federal USA hospitals with emergency departments to determine the availability of CT scanners capable of imaging obese patients. 57 They located two 500 lb (227 kg) weight capacity scanners in their sample of hospitals and eight in the 136 academic centers they contacted. In addition, they contacted 145 zoos and 28 veterinary schools to see if any of these facilities had scanners used for large animal studies which could be used for obese humans. Only two zoos had CT scanners; both would not image humans. Sixteen of the veterinary schools had large weight capacity scanners but only four would consider scanning humans. Most of the veterinary schools had policies specifically prohibiting imaging human patients. Therefore, the rumor that zoos and veterinary schools will perform CTPA on very obese patients with suspected PE is false.
The gantry size of a standard CT scanner is 70 cm in diameter, and the CT table occupies 15 cm of the vertical height of the gantry, limiting the available vertical height to 55 cm. There are obese patients who do not exceed a scanner's prescribed weight limit but cannot have a scan because their girth prevents them from fitting through the gantry. Manufacturers are now producing more 'heavyweight' scanners with larger gantry sizes and weight limits up to 660 lbs (300 kg) ( Table 3 ). There are no studies specifically examining the image quality of these 'heavyweight' scanners when used for CTPA in very obese patients.
Six percent of the CTPA studies in the PIOPED II study were deemed 'quality insufficient for conclusive interpretation' and were excluded from the study. 58 A retrospective review of 3612 CTPA reports by Jones and Wittram also showed a 6% rate of indeterminate studies, and body habitus was listed as a reason for the poor image quality in 7% of the indeterminate studies. 59 Eyer et al. reported a 9% inconclusive rate for CTPA in 1435 patients, and obesity was listed as one of the causes of these non-diagnostic studies. 60 Roggenland et al. studied the effect of weight on image quality in 126 patients undergoing CTPA. 61 They found that there was a significant negative correlation between patient weight and vessel enhancement, signal-to-noise ratio, contrast-to-noise ratio, and subjective image quality. In a retrospective study of 85 patients with weights up to 153 kg (337 lbs), Bae et al. examined the effect of patient weight on contrast enhancement in CTPA. 62 They showed that weight adversely affected contrast enhancement, frequently causing contrast enhancement in the pulmonary artery of less than 250 Hounsfield units, the level felt to be sufficient for PE studies. By adjusting the amount of contrast medium to the patient's weight, there was improvement in the contrast enhancement.
Magnetic resonance scanners are now being produced which can scan patients over 500 lbs (227 kg), but the recent PIOPED III study showed that 25% of the magnetic resonance pulmonary angiography studies done in patients with suspected PE were technically inadequate, causing an unacceptably low sensitivity rate of 57%. 63 The effect of obesity on the image quality of magnetic resonance pulmonary angiography has not been studied.
Implications for medical decision-making
With the increasing prevalence of morbidly obese patients, clinicians will more frequently be faced with obese patients with signs and symptoms suggestive of PE who either cannot receive thoracic imaging at their hospital because of their size or the imaging is inconclusive (see Figure 1 ). The clinician in this situation must first decide whether they should transfer the patient to another facility with a 'heavyweight' CT scanner. There are no guidelines to aid the physician in this situation. Locating these facilities is difficult since there is no website or national registry cataloging these CT scanners. In addition, risks are involved with such transfers, especially the risk of re-embolization during travel. Often there are questions about whether third party payors will provide reimbursement for these transfers. Finally, even though the patient may be transferred for the study, there is no guarantee that the study will be diagnostic since image quality may be poor, as described previously.
If diagnostic imaging is not possible, the decision whether or not to anticoagulate the obese patient with suspected PE is one of the most difficult clinical scenarios faced by physicians since there have been no studies examining the risk/benefit ratios of different approaches. It is doubtful that a prospective study will ever be performed to determine the approach with the best outcomes. Since untreated PE has a very high mortality rate, withholding therapy can lead to death if the patient actually has thromboembolic disease. However, anticoagulants are very highrisk medications, and anticoagulating patients without thromboembolic disease should be avoided if at all possible. Once empiric therapy is initiated, determining the proper duration of therapy can be problematic, especially if obesity is the only identifiable risk factor. D-dimer measurement several weeks after discontinuing the anticoagulation has been used to assess the ongoing risk of thromboembolic disease in the general population. 64 However, the usefulness of this approach in the obese population who may have chronically elevated D-dimer levels 16, 36 is unclear. The bleeding risk is 2-3% per year and the mortality per bleeding episode is 11-13% in patients anticoagulated for thromboembolic disease. 65, 66 The bleeding risk for obese patients taking warfarin has never been studied. In this situation, the clinician needs to make an empiric decision based on the clinical picture and the diagnostic studies which can be performed, even if the available studies may have some limitations because of the patient's body habitus. If the predicted risk of PE is low, it seems reasonable to withhold anticoagulation, follow the patient clinically, and consider serial LEVD studies. If the predicted risk is high, then therapeutic anticoagulation is indicated considering the high mortality rate of untreated PE. In patients with a moderate risk of PE, the decision is extremely difficult and needs to be made on a case-by-case basis. Six months of therapy with a follow-up D-dimer 3 weeks after discontinuing the Coumadin would seem to be a reasonable plan, but there are no clinical data available to support or refute this approach.
Summary
With the obesity epidemic continuing to escalate, clinicians will increasingly be faced with obese patients suspected of PE. As more hospitals acquire 'heavyweight' CT scanners, the ability to image the obese patient with suspected PE will improve, although problems with poor image quality will persist. Further clinical research is needed in this area, including studies on both image quality and outcomes in obese patients with suspected and proven PE.
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